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Abstract Decreased appetite and involuntary weight loss are
common occurrences in chronic disease and have a negative
impact on both quality of life and eventual mortality. Weight
lossinchronicdiseasecomesfrombothfatandleanmass,and
is known as cachexia. Both alterations in appetite and body
weight loss occur in a wide variety of diseases, including
cancer, heart failure, renal failure, chronic obstructive pulmo-
narydiseaseandHIV.Anincreaseincirculatinginflammatory
cytokines has been implicated as a uniting pathogenic
mechanism of cachexia and associated anorexia. One of the
targets of inflammatory mediators is the central nervous
system, and in particular feeding centers in the hypothalamus
located in the ventral diencephalon. Current research has
begun to elucidate the mechanisms by which inflammation
reaches the hypothalamus, and the neural substrates underly-
ing inflammatory anorexia. Research into these neural
mechanisms has suggested new therapeutic possibilities,
which have produced promising results in preclinical and
clinicaltrials.Thisreviewwilldiscussinflammatorysignaling
in the hypothalamus that mediates anorexia, and the oppor-
tunities for therapeutic intervention that these mechanisms
present.
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Decreased appetite (anorexia) and catabolism of lean
tissues are common co-morbidities of a multitude of
chronic diseases. In such diseases, the synergistic effects
of decreased energy intake on the one hand, and increased
energy expenditure on the other generate an ongoing loss of
body weight in which muscle mass is not appropriately
preserved [1]. Loss of muscle mass accompanying invol-
untary weight loss in association with chronic disease is
known as cachexia. The consensus definition of cachexia is
“… a complex metabolic syndrome associated with
underlying illness and characterized by the loss of muscle
with or without loss of fat mass” [2]. The presence of
cachexia is a negative prognostic indicator in a multitude of
conditions including cancer [3], chronic renal failure [4],
congestive heart failure (CHF) [5], and HIV [6]. Although
cachexia is not always associated with overt anorexia, they
often occur together [7]. Unlike starvation, where adipose
tissue is predominantly lost, muscle mass and adipose
tissue are both affected in cachexia [8]. In accordance with
this, correction of the nutritional deficit by intravenous
nutrition in cachexia, while beneficial, has been unsuccess-
ful in completely reversing the catabolic features of this
syndrome [9]. Therefore, a therapeutic modality that
corrects both decreased appetite and the catabolism of lean
mass is the most desirable for treating cachexia associated
with anorexia.
1 Cachexia as an inflammatory disease
One of the common features uniting all conditions
associated with cachexia is an increase in the levels of
circulating inflammatory cytokines. In chronic heart failure,
circulating levels of tumor necrosis factor (TNF) [10–12]
and interleukin-6 (IL-6) [11] are increased, and correlate
with the degree of exercise impairment in these patients. In
chronic renal failure, increased levels of circulating cyto-
kines and C-reactive protein are correlated with increased
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cachexia, multiple inflammatory cytokines have been found
at increased levels relative to non-cachectic cancer patients
including IL-6 [14, 15] and TNF [16, 17]. Furthermore,
multiple studies have implicated leukemia inhibitory factor
(LIF) as a pathogenic factor in cancer cachexia. LIF is
found at high levels in cancer patients [18], and is released
from human tumor cell lines [19]. While serum LIF levels
are a negative prognostic indicator in sepsis [20], no studies
have been performed to date correlating the circulating LIF
levels with the degree of cancer cachexia. Others have
failed to find elevated levels of the aforementioned
inflammatory mediators [17, 21] in cancer cachexia, likely
reflecting heterogeneity in the type and severity of cancer
studied as well as the intermittent nature of inflammatory
processes. The ability of these inflammatory molecules to
act directly on peripheral tissues to elicit catabolic
processes is well characterized [22, 23]. Increased inflam-
matory signaling in skeletal muscle potentiates myofibrillar
atrophy by suppressing protein synthesis and increasing
protein degradation. While clearly a critical pathway in the
pathogenesis of cachexia, there is at present no evidence for
the direct regulation of skeletal muscle catabolism by the
CNS, and it is therefore beyond the scope of this review.
2 The central nervous system as a target
of inflammatory signaling
It is well established that inflammatory cytokines have
potent effects on feeding in animal models. The peripheral
administration of cytokines such as interleukin-1 beta
(IL-1β)[ 24–26]a n dT N F[ 26] or the inflammatory
bacterial cell wall product lipopolysaccharide (LPS) [24,
25] potently induce anorexia in laboratory animals. Fur-
thermore, intercerebroventricular (ICV) injection of inflam-
matory cytokines such as IL-1β [27], LIF [28, 29], and
TNF [30] also reduce food intake, suggesting that the brain
can respond directly to inflammatory signals. Peripheral or
central cytokine injection leads to a rapid induction of
cFOS immunoreactivity, a marker of neuronal activation
[31], in multiple brain regions, including areas that are
critical for food intake and energy metabolism such as the
arcuate nucleus of the hypothalamus [32]. A negative
correlation has been reported in tumor-bearing animals
between food intake and interleukin 1 alpha concentration,
further implicating inflammatory cytokines in the patho-
genesis of anorexia [33].
Additional studies have suggested that inflammatory
cytokine production in the CNS itself is critical in the
generation of the anorectic response. Animals injected
peripherally with LPS display a rapid increase in the
expression of inflammatory cytokines in the hypothalamus
[24, 25]. IL-1β appears to be particularly critical, as ICV
infusion of IL-1 receptor antagonist (IL-1Ra) significantly
reduces the anorexia resulting from peripheral LPS admin-
istration, and normalizes hypothalamic cytokine expression
[34]. These results suggest that local cytokine production
within the brain may function as a critical signaling
intermediate and a feed forward mechanism for sustaining
the response to inflammation. Additional studies have
further implicated cytokine production within the brain as
a critical mediator of anorexia. Myeloid differentiation
primary response protein 88 (MyD88) is a signaling adaptor
downstream of toll-like receptor-4 (the cellular receptor for
LPS) and the type 1 interleukin-1 receptor (IL-1R1). Mice
lacking functional MyD88 evolve a normal or increased
serum cytokine response to LPS, presumably via MyD88-
independent pathways [24, 25]. However, these mice are
completely resistant to LPS- or IL-1β-induced anorexia and
show attenuated induction of hypothalamic cytokine pro-
duction. These data demonstrate the MyD88 dependence of
LPS-induced anorexia, and suggest that elevated hypotha-
lamic cytokine expression might be a critical intermediary.
The induction of IL-1β [35, 36]a n dT N F[ 36]
expression in the hypothalamus has been documented in
tumor-bearing animals. Further support for the critical
nature of hypothalamic cytokines comes from experiments
demonstrating that ICV administration of the TNF neutral-
izing antibody infliximab or IL-1Ra increases food intake
and reduces the febrile response in a cecal ligation and
puncture model of sepsis, and modestly increases survival
[37]. Additionally, ICV infliximab or IL-1Ra improve food
intake and survival in animals implanted with the
Walker-256 tumor [37], in which hypothalamic levels of
TNF and IL-1β are both increased. While promising, the
modest effects seen in these experiments point to likely
redundancies in the inflammatory control of anorexia in
more complex disease models. While many cytokines have
the capability of inducing anorexia when injected centrally,
the mRNA for multiple inflammatory mediators are
simultaneously induced in the hypothalamus after periph-
eral LPS challenge or in tumor-bearing animals. It is
therefore likely that in the true disease state, anorexia is
due to the additive or synergistic effects of multiple
inflammatory cytokines acting on both overlapping and
non-overlapping targets. Infusion of multiple cytokines at
doses that provoke only slight anorexia alone can lead to
dramatic anorexia when given in combination [27]. Fur-
thermore, the chronic administration of IL-1β, TNF, IL-6 or
interleukin-8 results in an initial anorectic period with rapid
desensitization and complete recovery of food intake by the
end of 1 week [38, 39]. In contrast, adenoviral delivery of
LIF to the CNS can generate a chronic anorexia and weight
loss that shows no signs of desensitization [40]. These
findings indicate that the generation of long lived disease-
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play of multiple CNS cytokines, which are likely specific to
the patient and condition.
3 Afferent pathways for inflammatory signaling
Visceral sensory afferents have been proposed as a potential
mechanism by which peripheral inflammation might gen-
erate an anorectic response. In particular, the vagus nerve
appears to play a role in mediating behavioral responses to
inflammation. Sub-diaphragmatic vagotomy was shown to
attenuate the induction of IL-1β mRNA expression in the
hypothalamus after intraperitoneal LPS challenge [41]o r
IL-1β injection [42]. However, other studies have demon-
strated that vagotomy does not prevent increases in
hypothalamic IL-1β protein content in LPS treated animals
[43]. In agreement with this, vagotomy was reported to
attenuate the anorexia seen with LPS administration [44]
while others have seen no alteration in the anorectic
response to LPS or other inflammatory stimuli in vagotom-
ized animals [45]. An explanation for the discordance of
these studies is not immediately apparent; however, these
data are suggestive of a vagally mediated anorectic pathway
in response to inflammatory stimuli that may be critical
under certain circumstances. It seems clear however, that
the vagus is not necessary for the anorectic response to
intravenous IL-1β [46] suggesting that inflammatory
cytokines in circulation may signal to the CNS via a
pathway independent of the vagus. There is some evidence
to suggest that tumor growth may stimulate anorexia via a
vagal pathway. Anorexia was attenuated in tumor-bearing
rats when a sub-diaphragmatic vagotomy was performed
prior to tumor implantation, or when vagal afferents were
chemically ablated [47].
In contrast multiple lines of evidence suggest that
circulating cytokines act directly on CNS neurons. The
best-studied cytokine with regard to its neuronal action is
leptin, a negative regulator of body mass and appetite.
While implicated as a mediator of uremic cachexia [48] and
elevated levels of leptin have been reported in CHF [49]
studies demonstrating the critical role for leptin in the
pathogenesis of other forms of cachexia have yet to be
performed. However, leptin is closely related to IL-6 and
LIF in structure and signaling [50]. Thus leptin may serve
as an effective prototype for cytokine access to the CNS,
despite extensive evidence for it being an essential mediator
of cachexia. Inflammatory cytokines are generally believed
to be too large to cross the blood brain barrier (BBB) by
simple diffusion [51]. However, CNS structures collectively
referred to as circumventricular organs have specialized
fenestrated capillaries. The median eminence is one such
region, where the permeable capillaries of the portal
vasculature play a critical role in the neuroendocrine
communication between the hypothalamus and the anterior
pituitary. Neurons in the adjacent arcuate nucleus of the
hypothalamus (ARC) are thought to have processes that lie
outside of the BBB [52] and are also responsive to
circulating factors via median eminence capillary fenestra-
tions [51]. Furthermore, the ARC is a critical site for the
integration of physiologic leptin signals. Thus, the ARC
represents a possible location for the detection of circulat-
ing cytokine signals. Additional areas of the brain respond
directly to leptin signals [53, 54], yet lie behind the BBB.
Active transport across the BBB and the blood-CSF barrier
is well characterized for leptin [55, 56]. In addition,
evidence exists for active transport into the CNS of multiple
inflammatory cytokines implicated in cachexia including
IL-1β [57]I L - 6[ 58], and TNF [59]. These data suggest the
possibility that areas of the brain that are behind the BBB
may be able to respond to circulating cytokines.
Another mode by which inflammatory cytokines may
influence neuronal activity is the synthesis of prostaglan-
dins along the BBB, either in endothelial cells or
perivascular macrophages. Prostaglandins are small lipid
soluble inflammatory mediators, which diffuse across the
BBB [60, 61]. Consistent with the notion that prostaglan-
dins serve as a signaling intermediate, endothelial and
perivascular cells express the receptors for inflammatory
cytokines [62, 63], and are activated under inflammatory
conditions [63, 64]. Furthermore, inflammatory insults
appear to activate endothelial cells more rapidly than
neurons. This suggests that under inflammatory conditions,
endothelial cells may be responsible for conveying the
activating signal to neurons [64]. In accordance with this,
neurons are known to express receptors for prostaglandins
[65]. Under inflammatory conditions, the mRNA for
synthetic enzymes for prostaglandin E2 (PGE2), the most
studied of the centrally acting prostaglandins, are induced
in endothelial cells and perivascular macrophages [66].
When cyclooxygenase (COX), the proximal biosynthetic
enzyme for prostaglandins, is blocked pharmacologically,
animals display attenuated anorexic responses to peripheral
IL-1β [67] and LPS [68, 69]. In some studies, tumor-
bearing animals display attenuated anorexia and weight loss
when treated with COX inhibitors [70, 71].
The precise mechanisms by which COX inhibition is
protective remains somewhat unclear, as certain tumors
show attenuated growth when treated with COX
inhibitors [72], suggesting that tumor regression rather
than inhibition of anorectic pathways may be responsible
for these effects. Furthermore, it appears that some
experimental tumors produce anorexia and weight loss
in a COX-independent manner, as COX inhibition is not
effective in reversing anorexia or weight loss in certain
models [71]. While the non-steroidal anti-inflammatory
J Cachexia Sarcopenia Muscle (2010) 1:135–145 137(NSAID) agents used to inhibit COX are generally
regarded as specific, recent evidence demonstrates that
many of the commonly used compounds also have the
ability to inhibit other inflammatory pathways including
nuclear factor-κB( N F - κB) [73]. This complicates the
interpretation of NSAID data, as the effects seen cannot
be solely attributed to decreases in prostaglandin biosyn-
thesis, and instead effects on other more general
inflammatory pathways must be considered. Additional
evidence for the role of prostaglandins in driving
anorexia and weight loss comes from studies in mice
lacking the terminal biosynthetic enzyme for PGE2,
microsomal prostaglandin E synthase. These mice dis-
play complete resistance to anorexia from LPS injection
or tumor implantation [74]. Interestingly, hypothalamic
expression of inflammatory cytokines is normally in-
duced under inflammatory conditions in these animals
suggesting parallel pathways for prostaglandin and
cytokine signaling.
4 Neural targets for inflammatory cytokine action:
the melanocortin system
One important target for inflammatory signaling in the CNS
is the hypothalamic central melanocortin system, which
consists of two neuronal populations expressing peptide
neurotransmitters with opposing actions (Fig. 1). Proopio-
melanocortin (POMC) neurons are located in the ARC, and
the nucleus of the solitary tract of the brain stem [75].
These neurons express the POMC precursor peptide, which
is cleaved into many bioactive products including the
anorectic peptide alpha melanocyte-stimulating hormone
(α-MSH). The anorectic effect of α-MSH is exerted by
binding to its cognate receptor, the type four melanocortin
receptor (MC4R), which is expressed in a broad array of
hypothalamic and extra-hypothalamic areas in the CNS
[76]. The net effect of signaling at the MC4R is decreased
appetite [77] and increased energy expenditure [78]. It
should be noted that the POMC peptide is cleaved into
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Fig. 1 Inflammatory cytokines
target hypothalamic feeding
circuits in cachexia. Inflamma-
tory cytokines from circulation
or produced locally by microglia
act directly on hypothalamic
arcuate nucleus neurons. The
activity of anorectic POMC
neurons is stimulated while the
activity of orexigenic AgRP/
NPY neurons is inhibited. This
leads to increased signaling at
the MC4R, which results in
decreased food intake and
increased energy expenditure.
Ghrelin analogs act by
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through the GHSR-1a while
melanocortin antagonists block
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functions. However, these other cleavage products are not
well described in cachexia, and have been extensively
reviewed elsewhere [79]. Lying adjacent to the arcuate
POMC neurons, are the Agouti-related peptide/neuropep-
tide Y (AgRP/NPY) neurons, which have orexigenic
activity [75]. While NPY acts on specific NPY receptors,
AgRP is an inverse agonist at the MC4R, increasing food
intake and decreasing energy expenditure [80]. Importantly,
α-MSH and AgRP immunoreactive fibers project to many
of the same locations across the CNS, although AgRP
projections are less dense [81–83]. In addition, AgRP
neurons send inhibitory projections to neighboring POMC
neurons, creating an additional level of control [84]. Both
neuronal populations are cytokine responsive. Furthermore,
both play a critical role in normal energy homeostasis in the
response to leptin, and the maladaptive energetic response
to inflammatory cytokines. In particular, POMC neurons
express the IL-1R1, and increase their spontaneous firing
rate in response to IL-1β administration. The release of
α-MSH from hypothalamic explants after IL-1β treatment
is also increased [85]. The converse is true of AgRP
neurons, which, like POMC neurons express the IL-1R1,
but instead decrease the spontaneous release of AgRP in
response to IL-1β [86]. Presumably, the net result of IL-1β
action on these two neuronal populations is to dramatically
increase signaling at the MC4R, resulting in anorexia. In
addition, recent work has shown that the acute anorectic
effects of exogenous LIF are entirely mediated by LIF
receptor signaling on POMC neurons [28], further demon-
strating the importance of the melanocortin system in
mediating the response to cytokines.
Additional evidence for the critical nature of melano-
cortin signaling in cachexia comes from the finding that
mice lacking functional MC4R resist anorexia associated
with tumor growth [87, 88], chronic renal failure [48], or
LPS administration [87, 88]. In addition, ICV administra-
tion of exogenous AgRP, or synthetic melanocortin antag-
onists also ameliorates anorexia induced by LPS,
inflammatory cytokines [26, 89, 90] chronic renal failure
[48], and tumor growth [88, 91].
As a result of these findings, multiple preclinical studies
have begun to examine the potential therapeutic benefit of
melanocortin antagonism in cachexia. Melanocortin antag-
onists have been developed that improve food intake and
prevent the loss of lean mass when administered peripher-
ally to tumor-bearing mice [90, 92]. Recently, melanocortin
antagonists have been developed with oral bioavailability
that attenuate anorexia and lean mass loss in tumor-bearing
animals [93]. Preclinical studies have also demonstrated the
efficacy of melanocortin antagonism in chronic renal
failure. Peripheral administration of melanocortin antago-
nists improves food intake [48] and prevents the loss of
lean mass in subtotal nephrectomy-induced chronic renal
failure [48, 94, 95]. As the preclinical data demonstrate,
melanocortin antagonism is an exciting treatment possibil-
ity for anorexia associated with chronic disease. Future
clinical studies will likely begin to explore the efficacy of
melanocortin antagonism as a therapeutic modality in
human cachexia.
5 Neural targets for inflammatory cytokine action:
neuropeptide Y
NPY is another well-studied orexigenic neuropeptide,
which increases food intake when administered exogenous-
ly. Co-expressed in the same neurons as AgRP, NPY is also
regulated by inflammatory stimuli. Globally, NPY acts to
increase food intake, and administration of exogenous NPY
leads to hyperphagia and obesity [96]. Unlike starvation,
which induces NPY mRNA in the hypothalamus, inflam-
matory stimuli such as LPS or IL-1β either show no change
[97] or demonstrate a reduction [98] in NPY mRNA levels.
Furthermore, tumor-bearing animals show either no change
[99], a decrease [100] or a slight increase [101] in NPY
mRNA, depending on the report. Irrespective of the
directionality of the change, inflammatory anorexia results
in a marked suppression of NPY mRNA expression relative
to that seen in animals restricted to an equivalent level of
food intake. This suggests that inflammatory signaling
disrupts the normal regulation of NPY in response to
negative energy balance.
A functional antagonism has been demonstrated between
IL-1β and NPY, where IL-β decreases the NPY-induced
feeding response in a dose-dependent manner [102]. A
reduction is seen in the NPY content of hypothalamic
microdialysates from tumor-bearing animals, suggesting
impaired NPY release in cachectic states [103]. However,
several studies have demonstrated a decreased efficacy of
exogenous NPY in tumor-bearing animals as compared
with healthy controls, suggesting functional resistance to
the peptide in cachexia [91, 104]. Furthermore, resistance to
continuous infusion of NPY develops rapidly in tumor-
bearing animals [104], suggesting an NPY deficiency is not
solely responsible for the anorexia in tumor-bearing
animals. In accordance with these studies, radioligand
binding assays performed in anorectic tumor-bearing rats
demonstrated a dramatic decrease in NPY receptor affinity
with a moderate reduction in receptor number [105].
Finally, decreases in NPY immunoreactive projections to
various hypothalamic nuclei have been documented in
anorectic animals [100]. These data collectively demon-
strate that NPY is aberrantly regulated in cachectic states.
There is evidence to suggest both a decrease in NPY
production, and a decreased sensitivity to NPY in cachexia.
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in cachexia, a therapeutic strategy involving exogenous
NPY replacement without correction of the underlying
downstream defects may not be viable.
6 Neural targets for inflammatory cytokine action:
the serotonergic system
The serotonergic system is a powerful regulator of food
intake and energy metabolism. Serotonergic neurons are
located in the brainstem raphe nuclei and project to a wide
variety of cortical and subcortical regions. Serotonin or
5-hydroxytrypamine (5-HT) is released from the terminals
of these neurons and binds to 5-HT receptors. There are
seven families of serotonin receptors (5-HT1–7R), each of
which contains multiple members, with overlapping roles in
cognition, memory, and autonomic functions such as
vasomotor tone and GI motility [106]. As a result, serotonin
biology is a complex field that cannot be fully reviewed
here, and references will only be made to aspects that have
been implicated in cachexia.
Global activation of the serotonin system appears to
suppress feeding. Administration of the drug fenfluramine,
which is believed to globally increase serotonin release and
simultaneously block reuptake, suppresses feeding in
animals and humans [107–109]. Furthermore, lesions of
the raphe nuclei [110] or ICV injection of a serotonin
antagonist [111] result in hyperphagia and obesity. The
majority of studies have focused on the 5-HT2CR as the
predominant receptor mediating the effects of serotonin
signaling on appetite. Mice lacking functional 5-HT2CR
resist the effects of fenfluramine or a specific 5-HT2C R
agonist [112, 113] on food intake and develop obesity
secondary to hyperphagia [114]. Interestingly, ARC POMC
neurons express 5-HT2C R and are activated electrophysi-
ologically by fenfluramine [115]. In the context of the 5-
HT2C R deficient mouse, selective restoration of 5-HT2C R
expression in POMC neurons corrects the obese phenotype
[116].
Experimental evidence for the involvement of serotoner-
gic signaling in disease-associated anorexia comes from
work examining the serotonin content of the hypothalamic
ventromedial nucleus (VMH). Microdialysis experiments
revealed an increase in VMH serotonin content in tumor-
bearing animals, which returned to baseline with tumor
excision [117]. Furthermore, injection of a serotonin
antagonist into the VMH of tumor-bearing animals resulted
in improved food intake [53]. Another study, however,
found no effect on the appetite of tumor bearing mice
treated with tricyclic antidepressants, which are generally
believed to inhibit serotonin reuptake and potentiate its
signaling [118]. While serotonin signaling seems a likely
candidate for therapy, future studies will have to be
performed to examine receptor subtypes involved in
inflammatory anorexia.
7 Neural targets for inflammatory cytokine action:
ghrelin
Ghrelin is a growth hormone releasing peptide, which is
produced in the stomach in response to hunger or starvation
[119]. Ghrelin is present in two forms: acylated ghrelin
which is active, and desacyl ghrelin which is inactive. Acyl
ghrelin binds to the growth hormone secretogogue receptor-
1a (GHSR-1a) which is found on ARC AgRP/NPY
neurons, increasing their activity and peptide release
[120]. There is some experimental evidence for the
involvement of ghrelin the in the pathophysiology of
cachexia. Ghrelin exerts anti-inflammatory effects on
immune cells and endothelium [121, 122], decreasing
proinflammatory cytokine production. In animals and
humans experiencing anorexia due to inflammatory arthri-
tis, serum ghrelin levels are decreased compared with
controls [123]. Furthermore, ghrelin levels are acutely
decreased by LPS administration [124], which results in
an IL-1R1 and prostacyclin-dependent signaling mecha-
nism decreasing ghrelin secretion by the stomach [125]. In
contrast to the acute inflammatory state however, ghrelin is
found at increased levels in chronic inflammation. Further-
more, exogenous ghrelin administration attenuates the
anorectic response to LPS [122], most likely due to an
attenuation of the inflammatory response and activation of
hypothalamic AgRP/NPY neurons.
However, plasma levels of ghrelin are increased in
patients with cachexia from multiple etiologies as compared
with non-cachectic patients suffering from the same
underlying conditions [126–129] although some do report
that levels fall in advanced cancer patients [130]. This
suggests that in cachexia, ghrelin may be elevated as a
compensatory mechanism for negative energy balance.
Based on these human data, an overt ghrelin deficiency
does not appear to be involved in the pathogenesis of
anorexia associated with chronic disease, although the
possibility remains that the ghrelin response is inappropri-
ately low given the level of negative energy balance.
Despite the lack of conclusive evidence for a clear role for
ghrelin in chronic anorexia, multiple preclinical studies have
demonstrated promising results in experimental models of
cachexia. When administered to tumor-bearing animals [99,
131, 132] or rats with chronic renal failure [133], ghrelin
ameliorates anorexia and improves lean mass. Interestingly,
ghrelin administration appears to improve skeletal muscle
mitochondrial oxidative capacity independent of food intake
[134], suggesting that ghrelin may have peripheral anti-
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lamic anti-catabolic pathway. When utilized in an experimen-
tal model of CHF, ghrelin treatment improves muscle mass
[135] and overall lean mass [136]. These promising data have
resulted in multiple clinical trials examining the efficacy of
ghrelin in cachexia of multiple etiologies.
8 Current and future therapy for decreased appetite
in chronic disease
Few theraputic options exist currently for the treatment of
anorexia in chronic disease. Progestational agents such as
megesterol acetate have been effective in improving food
intake, and produce significant weight gain. However, the
weight gain associated with its use is mostly due to
increased fat and water mass [137, 138]. Treatment with
exogenous ghrelin and ghrelin analogs however, has been
very successful in early clinical trials in patients suffering
from cachexia resulting from several underlying disorders.
In patients with CHF, ghrelin administration improved
exercise capacity, and increased lean body mass and muscle
strength [139]. Ghrelin also improves food intake, perfor-
mance status, muscle strength, and lean mass in chronic
obstructive pulmonary disease [140]. Early studies in
cancer cachexia have been less compelling. A phase I
study showed that ghrelin was well tolerated by cancer
patients, but no differences were observed in nutritional
intake or body weight [141], although food intake did trend
toward improvement. Single injection of ghrelin into
cachechtic cancer [142] and renal failure [143] patients
improved immediate post-injection food intake in both
groups. Further studies are currently underway to study the
efficacy of ghrelin treatment in larger groups of cachectic
patients, with the hope of introducing ghrelin as a standard
treatment option in cachexia.
9 Conclusions
The anorexia associated with chronic disease is a multifac-
torial process that is variable and likely dependent on the
etiology of the underlying disease. Many inflammatory
molecules appear to be sufficient to cause reduced food
intake in animal models acutely, but sustained decreases in
food intake as occur in cachectic patients may be driven by
a specific subset of inflammatory mediators, or the
combined action of multiple mediators acting simultaneous-
ly. While numerous brain regions are activated by inflam-
mation, only a few neuronal subtypes have been identified
that respond directly to inflammatory cytokines. Whether
ARC POMC and AgRP neurons represent an integrator of
inflammatory cytokine signaling, or other as yet unidenti-
fied neurons are also directly responsive to these cytokines
remains to be elucidated. Regardless, agents targeting these
neurons or their downstream receptor the MC4R have been
remarkably effective in preclinical studies and early clinical
trials. It is likely that the best outcomes for anorectic
patients will be obtained by combination therapy targeting
both inflammatory mediators and their neural targets.
Acknowledgments The authors of this manuscript certify that they
comply with the ethical guidelines for authorship and publishing in the
Journal of Cachexia, Sarcopenia and Muscle [144].
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst.
1997;89:1763–73.
2. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge
D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.
3. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer.
2002;2:862–71.
4. WangAY-M,SeaMM-M,TangN,SandersonJE,LuiS-F,LiPK-T,
et al. Resting energy expenditure and subsequent mortality risk in
peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:3134–43.
5. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL,
Webb-Peploe KM, et al. Wasting as independent risk factor for
mortality in chronic heart failure. Lancet. 1997;349:1050–3.
6. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of
body-cell-mass depletion and the timing of death from wasting in
AIDS. Am J Clin Nutr. 1989;50:444–7.
7. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake
and resting energy expenditure in relation to weight loss in
unselected cancer patients. Int J Cancer. 2001;93:380–3.
8. Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell
mass in cancer-bearing and anorexic patients. JPEN J Parenter
Enteral Nutr. 1987;11:219–22.
9. Evans WK, Makuch R, Clamon GH, Feld R, Weiner RS, Moran
E, et al. Limited impact of total parenteral nutrition on nutritional
status during treatment for small cell lung cancer. Cancer Res.
1985;45:3347–53.
10. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated
circulating levels of tumor necrosis factor in severe chronic heart
failure. N Engl J Med. 1990;323:236–41.
11. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB,
Mann DL. Proinflammatory cytokine levels in patients with
depressed left ventricular ejection fraction: a report from the
Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll
Cardiol. 1996;27:1201–6.
12. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C,
Sharma R, et al. High tumour necrosis factor-alpha levels are
associated with exercise intolerance and neurohormonal
activation in chronic heart failure patients. Cytokine. 2001;15:
80–6.
13. Kalantar-Zadeh K, Stenvinkel P, Bross R, Khawar OS, Rammohan
M, Colman S, et al. Kidney insufficiency and nutrient-based
modulation of inflammation. Curr Opin Clin Nutr Metab Care.
2005;8:388–96.
J Cachexia Sarcopenia Muscle (2010) 1:135–145 14114. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The
relationship between weight loss and interleukin 6 in non-small-
cell lung cancer. Br J Cancer. 1996;73:1560–2.
15. Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB,
Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1,
interleukin-6, and tumor necrosis factor-alpha in patients with
ovarian epithelial cancer. Cancer. 1993;72:2433–40.
16. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M,
Bounovas A, Simopoulos K. Serum levels of tumor necrosis
factor-alpha and nutritional status in pancreatic cancer patients.
Anticancer Res. 2001;21:1355–8.
17. Tas F, Duranyildiz D, Argon A, Oğuz H, Camlica H, Yasasever
V, et al. Serum levels of leptin and proinflammatory cytokines in
advanced-stage non-small cell lung cancer. Med Oncol.
2005;22:353–8.
18. Gouin F, Heymann D, Raher S, De Groote D, Passuti N, Daculsi
G, et al. Increased levels of leukaemia inhibitory factor (LIF) in
urine and tissue culture supernatant from human primary bone
tumours. Cytokine. 1998;10:110–4.
19. Gascan H, Anegón I, Praloran V, Naulet J, Godard A, Soulillou
JP, et al. Constitutive production of human interleukin for DA
cells/leukemia inhibitory factor by human tumor cell lines
derived from various tissues. J Immunol. 1990;144:2592–8.
20. Villers D, Dao T, Nguyen JM, Bironneau E, Godard A, Moreau
M, et al. Increased plasma levels of human interleukin for DA1.a
cells/leukemia inhibitory factor in sepsis correlate with shock
and poor prognosis. J Infect Dis. 1995;171:232–6.
21. Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E,
et al. Serum levels of tumour necrosis factor alpha and other
cytokines do not correlate with weight loss and anorexia in
cancer patients. Support Care Cancer. 1997;5:130–5.
22. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling
pathways. Int J Biochem Cell Biol. 2005;37:1974–84.
23. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways
continue to emerge yet much still points to the proteasome. Clin
Cancer Res. 2007;13:1356–61.
24. Wisse BE, Ogimoto K, Tang J, Harris MK, Raines EW, Schwartz
MW. Evidence that lipopolysaccharide-induced anorexia
depends upon central, rather than peripheral, inflammatory
signals. Endocrinology. 2007;148:5230–7.
25. Ogimoto K, Harris MK, Wisse BE. MyD88 is a key mediator of
anorexia, but not weight loss, induced by lipopolysaccharide and
interleukin-1 beta. Endocrinology. 2006;147:4445–53.
26. Whitaker KW, Reyes TM. Central blockade of melanocortin
receptors attenuates the metabolic and locomotor responses to
peripheral interleukin-1beta administration. Neuropharmacology.
2008;54:509–20.
27. Sonti G, Ilyin SE, Plata-Salamán CR. Anorexia induced by
cytokine interactions at pathophysiological concentrations. Am J
Physiol. 1996;270:R1394–1402.
28. Grossberg AJ, Scarlett JM, Zhu X, Bowe DD, Batra AK, Braun
TP, et al. Arcuate nucleus proopiomelanocortin neurons mediate
the acute anorectic actions of leukemia inhibitory factor via
gp130. Endocrinology. 2010;151:606–16.
29. Plata-Salamán CR. Anorexia induced by activators of the signal
transducer gp 130. NeuroReport. 1996;7:841–4.
30. Bodnar RJ, Pasternak GW, Mann PE, Paul D, Warren R, Donner
DB. Mediation of anorexia by human recombinant tumor
necrosis factor through a peripheral action in the rat. Cancer
Res. 1989;49:6280–4.
31. Morgan JI, Curran T. Role of ion flux in the control of c-fos
expression. Nature. 1986;322:552–5.
32. Elmquist JK, Scammell TE, Jacobson CD, Saper CB. Distribu-
tion of Fos-like immunoreactivity in the rat brain following
intravenous lipopolysaccharide administration. J Comp Neurol.
1996;371:85–103.
33. Opara EI, Laviano A, Meguid MM, Yang ZJ. Correlation
between food intake and CSF IL-1 alpha in anorectic tumor
bearing rats. NeuroReport. 1995;6:750–2.
34. Layé S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzer R,
et al. Endogenous brain IL-1 mediates LPS-induced anorexia and
hypothalamic cytokine expression. Am J Physiol Regul Integr
Comp Physiol. 2000;279:R93–98.
35. Plata-Salamán CR, Ilyin SE, Gayle D. Brain cytokine mRNAs in
anorectic rats bearing prostate adenocarcinoma tumor cells. Am J
Physiol. 1998;275:R566–573.
36. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT,
Morari J, et al. A central role for neuronal adenosine
5′-monophosphate-activated protein kinase in cancer-induced
anorexia. Endocrinology. 2007;148:5220–9.
37. Arruda AP, Milanski M, Romanatto T, Solon C, Coope A,
Alberici LC, et al. Hypothalamic actions of tumor necrosis factor
alpha provide the thermogenic core for the wastage syndrome in
cachexia. Endocrinology. 2010;151:683–94.
38. Hill AG, Jacobson L, Gonzalez J, Rounds J, Majzoub JA,
Wilmore DW. Chronic central nervous system exposure to
interleukin-1 beta causes catabolism in the rat. Am J Physiol.
1996;271:R1142–1148.
39. Plata-Salamán CR, Sonti G, Borkoski JP, Wilson CD, French-
Mullen JM. Anorexia induced by chronic central administration
of cytokines at estimated pathophysiological concentrations.
Physiol Behav. 1996;60:867–75. 04189@brahmsudeledu.
40. Beretta E, Dhillon H, Kalra PS, Kalra SP. Central LIF gene
therapy suppresses food intake, body weight, serum leptin and
insulin for extended periods. Peptides. 2002;23:975–84.
41. Layé S, Bluthé RM, Kent S, Combe C, Médina C, Parnet P, et al.
Subdiaphragmatic vagotomy blocks induction of IL-1 beta
mRNA in mice brain in response to peripheral LPS. Am J
Physiol. 1995;268:R1327–1331.
42. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the
induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats
in response to systemic IL-1beta. J Neurosci. 1998;18:2247–53.
43. Hansen MK, Nguyen KT, Goehler LE, Gaykema RP, Fleshner
M, Maier SF, et al. Effects of vagotomy on lipopolysaccharide-
induced brain interleukin-1beta protein in rats. Auton Neurosci.
2000;85:119–26.
44. Bret-Dibat JL, Bluthé RM, Kent S, Kelley KW, Dantzer R.
Lipopolysaccharide and interleukin-1 depress food-motivated
behavior in mice by a vagal-mediated mechanism. Brain Behav
Immun. 1995;9:242–6.
45. Porter MH, Hrupka BJ, Langhans W, Schwartz GJ. Vagal and
splanchnic afferents are not necessary for the anorexia produced
by peripheral IL-1beta, LPS, and MDP. Am J Physiol. 1998;275:
R384–389.
46. Pitterman AB, Friedlander G, Kelly G, Ropchak TG, Goldstein
DJ, Keiser HR. Abdominal vagotomy does not modify endotoxic
shock in rats. Life Sci. 1983;33:1033–7.
47. Bernstein IL. Neutral mediation of food aversions and anorexia
induced by tumor necrosis factor and tumors. Neurosci Biobehav
Rev. 1996;20:177–81.
48. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH.
Role of leptin and melanocortin signaling in uremia-associated
cachexia. J Clin Invest. 2005;115:1659–65.
49. Doehner W, Pflaum CD, Rauchhaus M, Godsland IF, Egerer K,
Cicoira M, et al. Leptin, insulin sensitivity and growth hormone
binding protein in chronic heart failure with and without cardiac
cachexia. Eur J Endocrinol. 2001;145:727–35.
50. La Cava A, Matarese G. The weight of leptin in immunity. Nat
Rev Immunol. 2004;4:371–9.
51. Münzberg H. Differential leptin access into the brain–a hierar-
chical organization of hypothalamic leptin target sites? Physiol
Behav. 2008;94:664–9.
142 J Cachexia Sarcopenia Muscle (2010) 1:135–14552. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ.
The arcuate nucleus as a conduit for diverse signals relevant to
energy homeostasis. Int J Obes Relat Metab Disord. 2001;25
Suppl 5:S63–67.
53. Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C,
Rossi Fanelli F. Effects of intra-VMN mianserin and IL-1ra on
meal number in anorectic tumor-bearing rats. J Investig Med.
2000;48:40–8.
54. Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V,
et al. Leptin directly activates SF1 neurons in the VMH, and this
action by leptin is required for normal body-weight homeostasis.
Neuron. 2006;49:191–203.
55. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S, Farrell
CL. Differential regulation of leptin transport by the choroid
plexus and blood-brain barrier and high affinity transport
systems for entry into hypothalamus and across the blood-
cerebrospinal fluid barrier. Endocrinology. 2000;141:1434–41.
56. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines
across the blood-brain barrier. Neuroimmunomodulation.
1995;2:241–8.
57. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin
(IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are
transported from blood to brain in the mouse by a shared
saturable mechanism. J Pharmacol Exp Ther. 1991;259:988–96.
58. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6
across the murine blood-brain barrier. Neurosci Lett.
1994;179:53–6.
59. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis
factor alpha is transported from blood to brain in the mouse. J
Neuroimmunol. 1993;47:169–76.
60. Elmquist JK, Breder CD, Sherin JE, Scammell TE, Hickey WF,
Dewitt D, et al. Intravenous lipopolysaccharide induces cyclo-
oxygenase 2-like immunoreactivity in rat brain perivascular
microglia and meningeal macrophages. J Comp Neurol.
1997;381:119–29.
61. Ericsson A, Arias C, Sawchenko PE. Evidence for an intra-
medullary prostaglandin-dependent mechanism in the activation
of stress-related neuroendocrine circuitry by intravenous
interleukin-1. J Neurosci. 1997;17:7166–79.
62. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ,
Ericsson-Dahlstrand A. Inflammatory response: pathway across
the blood-brain barrier. Nature. 2001;410:430–1.
63. Nadeau S, Rivest S. Effects of circulating tumor necrosis factor on
the neuronal activity and expression of the genes encoding the
tumornecrosisfactorreceptors(p55andp75)intheratbrain:aview
from the blood-brain barrier. Neuroscience. 1999;93:1449–64.
64. Herkenham M, Lee HY, Baker RA. Temporal and spatial
patterns of c-fos mRNA induced by intravenous interleukin-1:
a cascade of non-neuronal cellular activation at the blood-brain
barrier. J Comp Neurol. 1998;400:175–96.
65. Nakamura K, Kaneko T, Yamashita Y, Hasegawa H, Katoh H,
Negishi M. Immunohistochemical localization of prostaglandin
EP3 receptor in the rat nervous system. J Comp Neurol.
2000;421:543–69.
66. Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes
TM, Sawchenko PE. Dual roles for perivascular macrophages in
immune-to-brain signaling. Neuron. 2010;65:94–106.
67. Shimomura Y, Inukai T, Kuwabara S, Shimizu H, Takahashi M,
Sato N, et al. Both cyclooxygenase and lipoxygenase inhibitor
partially restore the anorexia by interleukin-1 beta. Life Sci.
1992;51:1419–26.
68. Langhans W, Harlacher R, Scharrer E. Verapamil and indometh-
acin attenuate endotoxin-induced anorexia. Physiol Behav.
1989;46:535–9.
69. Johnson PM, Vogt SK, Burney MW, Muglia LJ. COX-2
inhibition attenuates anorexia during systemic inflammation
without impairing cytokine production. Am J Physiol Endocrinol
Metab. 2002;282:E650–656.
70. Davis TW, Zweifel BS, O’Neal JM, Heuvelman DM, Abegg AL,
Hendrich TO, et al. Inhibition of cyclooxygenase-2 by celecoxib
reverses tumor-induced wasting. J Pharmacol Exp Ther.
2004;308:929–34.
71. Strelkov AB, Fields AL, Baracos VE. Effects of systemic
inhibition of prostaglandin production on protein metabolism in
tumor-bearing rats. Am J Physiol. 1989;257:C261–269.
72. Piffar PM, Fernandez R, Tchaikovski O, Hirabara SM, Folador
A, Pinto GJ, et al. Naproxen, clenbuterol and insulin adminis-
tration ameliorates cancer cachexia and reduce tumor growth in
Walker 256 tumor-bearing rats. Cancer Lett. 2003;201:139–48.
73. Davis MP. Anti-inflammatory agents in cancer cachexia. In:
Hofbauer SDA Karl G, Akio Inui, Nicholson Janet R, editors.
Pharmacotherapy of Cachexia. New York: Taylor & Francis;
2006. p. 369–82.
74. Pecchi E, Dallaporta M, Jean A, Thirion S, Troadec JD. mPGES-
1 knock-out mice are resistant to cancer-induced anorexia despite
the absence of central mPGES-1 up-regulation in wild-type
anorexic mice. J Neuroimmunol. 2008;199:104–14.
75. Cone RD. Anatomy and regulation of the central melanocortin
system. Nat Neurosci. 2005;8:571–8.
76. Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB,
Elmquist JK. Expression of melanocortin 4 receptor mRNA in
the central nervous system of the rat. J Comp Neurol.
2003;457:213–35.
77. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of
melanocortinergic neurons in feeding and the agouti obesity
syndrome. Nature. 1997;385:165–8.
78. Frigeri LG, Wolff GL, Teguh C. Differential responses of yellow
Avy/A and agouti A/a (BALB/c X VY) F1 hybrid mice to the
same diets: glucose tolerance, weight gain, and adipocyte
cellularity. Int J Obes. 1988;12:305–20.
79. Pritchard LE, Turnbull AV, White A. Pro-opiomelanocortin
processing in the hypothalamus: impact on melanocortin
signalling and obesity. J Endocrinol. 2002;172:411–21.
80. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y,
Gantz I, et al. Antagonism of central melanocortin receptors
in vitro and in vivo by agouti-related protein. Science.
1997;278:135–8.
81. Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I,
Akil H, Barsh GS, Watson SJ (1999) Anatomy of an endogenous
antagonist: relationship between Agouti-related protein and
proopiomelanocortin in brain. J Neurosci 19:RC26
82. Haskell-Luevano C, Chen P, Li C, Chang K, Smith MS,
Cameron JL, et al. Characterization of the neuroanatomical
distribution of agouti-related protein immunoreactivity in the
rhesus monkey and the rat. Endocrinology. 1999;140:1408–15.
83. Jacobowitz DM, O’Donohue TL. alpha-Melanocyte stimulating
hormone: immunohistochemical identification and mapping in
neurons of rat brain. Proc Natl Acad Sci USA. 1978;75:6300–4.
84. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S,
Horvath TL, et al. Leptin activates anorexigenic POMC neurons
through a neural network in the arcuate nucleus. Nature.
2001;411:480–4.
85. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant
WF, et al. Regulation of central melanocortin signaling by
interleukin-1 beta. Endocrinology. 2007;148:4217–25.
86. Scarlett JM, Zhu X, Enriori PJ, Bowe DD, Batra AK, Levasseur
PR, et al. Regulation of agouti-related protein messenger
ribonucleic acid transcription and peptide secretion by acute
and chronic inflammation. Endocrinology. 2008;149:4837–45.
87. Marks DL, Butler AA, Turner R, Brookhart G, Cone RD.
Differential role of melanocortin receptor subtypes in cachexia.
Endocrinology. 2003;144:1513–23.
J Cachexia Sarcopenia Muscle (2010) 1:135–145 14388. Marks DL, Ling N, Cone RD. Role of the central melanocortin
system in cachexia. Cancer Res. 2001;61:1432–8.
89. Joppa MA, Ling N, Chen C, Gogas KR, Foster AC, Markison S.
Central administration of peptide and small molecule MC4
receptor antagonists induce hyperphagia in mice and attenuate
cytokine-induced anorexia. Peptides. 2005;26:2294–301.
90. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare
SRJ, et al. The regulation of feeding and metabolic rate and the
prevention of murine cancer cachexia with a small-molecule
melanocortin-4 receptor antagonist. Endocrinology. 2005;
146:2766–73.
91. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of
cancer anorexia by blockade of central melanocortin receptors in
rats. Endocrinology. 2001;142:3292–301.
92. Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P,
Hofbauer KG. Peripheral administration of a melanocortin
4-receptor inverse agonist prevents loss of lean body mass
in tumor-bearing mice. J Pharmacol Exp Ther. 2006;317:
771–7.
93. Weyermann P, Dallmann R, Magyar J, Anklin C, Hufschmid M,
Dubach-Powell J, et al. Orally available selective melanocortin-4
receptor antagonists stimulate food intake and reduce cancer-
induced cachexia in mice. PLoS ONE. 2009;4:e4774.
94. Cheung WW, Kuo H-J, Markison S, Chen C, Foster AC, Marks
DL, et al. Peripheral administration of the melanocortin-4
receptor antagonist NBI-12i ameliorates uremia-associated
cachexia in mice. J Am Soc Nephrol. 2007;18:2517–24.
95. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of
melanocortin signaling ameliorates uremic cachexia. Kidney Int.
2008;74:180–6.
96. Chee MJS, Colmers WF. Y eat? Nutrition. 2008;24:869–77.
97. Sergeyev V, Broberger C, Hökfelt T. Effect of LPS administra-
tion on the expression of POMC, NPY, galanin, CARTand MCH
mRNAs in the rat hypothalamus. Brain Res Mol Brain Res.
2001;90:93–100.
98. Gayle D, Ilyin SE, Plata-Salamán CR. Central nervous system
IL-1 beta system and neuropeptide Y mRNAs during IL-1 beta-
induced anorexia in rats. Brain Res Bull. 1997;44:311–7.
99. Deboer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui
A, et al. Ghrelin treatment causes increased food intake and
retention of lean body mass in a rat model of cancer cachexia.
Endocrinology. 2007;148:3004–12.
100. Makarenko IG, Meguid MM, Gatto L, Chen C, Ugrumov MV.
Decreased NPY innervation of the hypothalamic nuclei in rats
with cancer anorexia. Brain Res. 2003;961:100–8.
101. Nara-ashizawa N, Tsukada T, Maruyama K, Akiyama Y,
Kajimura N, Yamaguchi K. Response of hypothalamic NPY
mRNAs to a negative energy balance is less sensitive in
cachectic mice bearing human tumor cells. Nutr Cancer.
2001;41:111–8.
102. Sonti G, Ilyin SE, Plata-Salamán CR. Neuropeptide Y blocks
and reverses interleukin-1 beta-induced anorexia in rats.
Peptides. 1996;17:517–20.
103. Chance WT, Balasubramaniam A, Dayal R, Brown J, Fischer JE.
Hypothalamic concentration and release of neuropeptide Y into
microdialysates is reduced in anorectic tumor-bearing rats. Life
Sci. 1994;54:1869–74.
104. Chance WT, Balasubramaniam A, Thompson H, Mohapatra B,
Ramo J, Fischer JE. Assessment of feeding response of tumor-
bearing rats to hypothalamic injection and infusion of neuropep-
tide Y. Peptides. 1996;17:797–801.
105. Chance WT, Balasubramaniam A, Fischer JE. Neuropeptide Y
and the development of cancer anorexia. Ann Surg.
1995;221:579–87. discussion 587–579.
106. Tecott LH. Serotonin and the orchestration of energy balance.
Cell Metab. 2007;6:352–61.
107. Blundell JE, Leshem MB. The effect of 5-hydroxytryptophan on
food intake and on the anorexic action of amphetamine and
fenfluramine. J Pharm Pharmacol. 1975;27:31–7.
108. Rowland NE, Carlton J. Neurobiology of an anorectic drug:
fenfluramine. Prog Neurobiol. 1986;27:13–62.
109. McGuirk J, Goodall E, Silverstone T, Willner P. Differential
effects of d-fenfluramine, l-fenfluramine and d-amphetamine on
the microstructure of human eating behaviour. Behav Pharmacol.
1991;2:113–9.
110. Geyer MA, Puerto A, Menkes DB, Segal DS, Mandell AJ.
Behavioral studies following lesions of the mesolimbic and
mesostriatal serotonergic pathways. Brain Res. 1976;106:257–69.
111. Saller CF, Stricker EM. Hyperphagia and increased growth in
rats after intraventricular injection of 5, 7-dihydroxytryptamine.
Science. 1976;192:385–7.
112. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced
satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor
mutant mice. Psychopharmacol Berl. 1999;143:309–14.
113. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH,
Dallman MF, et al. Eating disorder and epilepsy in mice lacking
5-HT2c serotonin receptors. Nature. 1995;374:542–6.
114. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-
independent hyperphagia and type 2 diabetes in mice with a
mutated serotonin 5-HT2C receptor gene. Nat Med.
1998;4:1152–6.
115. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL,
et al. Activation of central melanocortin pathways by fenflur-
amine. Science. 2002;297:609–11.
116. Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ, et al.
5-HT2CRs expressed by pro-opiomelanocortin neurons regulate
energy homeostasis. Neuron. 2008;60:582–9.
117. Bláha V, Yang ZJ, Meguid MM, Chai JK, Oler A, Zadák Z.
Ventromedial nucleus of hypothalamus is related to the develop-
ment of cancer-induced anorexia: in vivo microdialysis study.
Acta Med Hradec Kralove. 1998;41:3–11.
118. Wang W, Danielsson A, Svanberg E, Lundholm K. Lack of
effects by tricyclic antidepressant and serotonin inhibitors on
anorexia in MCG 101 tumor-bearing mice with eicosanoid-
related cachexia. Nutrition. 2003;19:47–53.
119. Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH. Ghrelin
in the regulation of body weight and metabolism. Front Neuro-
endocrinol. 2010;31:44–60.
120. Willesen MG, Kristensen P, Rømer J. Co-localization of
growth hormone secretagogue receptor and NPY mRNA in
the arcuate nucleus of the rat. Neuroendocrinology.
1999;70:306–16.
121. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et
al. Ghrelin inhibits proinflammatory responses and nuclear
factor-kappaB activation in human endothelial cells. Circulation.
2004;109:2221–6.
122. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK,
Palaniappan R, et al. Ghrelin inhibits leptin- and activation-
induced proinflammatory cytokine expression by human mono-
cytes and T cells. J Clin Investig. 2004;114:57–66.
123. Otero M, Nogueiras R, Lago F, Dieguez C, Gomez-Reino JJ,
Gualillo O. Chronic inflammation modulates ghrelin levels in
humans and rats. Rheumatol Oxf. 2004;43:306–10.
124. Basa NR, Wang L, Arteaga JR, Heber D, Livingston EH, Taché
Y. Bacterial lipopolysaccharide shifts fasted plasma ghrelin to
postprandial levels in rats. Neurosci Lett. 2003;343:25–8.
125. Madison LD, Scarlett JM, Levasseur P, Zhu X, Newcomb K,
Batra A, et al. Prostacyclin signaling regulates circulating
ghrelin during acute inflammation. J Endocrinol.
2008;196:263–73.
126. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M,
Okumura H, et al. Elevated circulating level of ghrelin in
144 J Cachexia Sarcopenia Muscle (2010) 1:135–145cachexia associated with chronic heart failure: relationships
between ghrelin and anabolic/catabolic factors. Circulation.
2001;104:2034–8.
127. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda
H, et al. Increased plasma ghrelin level in lung cancer cachexia.
Clin Cancer Res. 2003;9:774–8.
128. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N,
et al. Adiponectin, ghrelin, and leptin in cancer cachexia in
breast and colon cancer patients. Cancer. 2006;106:966–73.
129. Takahashi M, Terashima M, Takagane A, Oyama K, Fujiwara H,
Wakabayashi G. Ghrelin and leptin levels in cachectic patients with
cancer of the digestive organs. Int J Clin Oncol. 2009;14:315–20.
130. Legakis I, Stathopoulos J, Matzouridis T, Stathopoulos GP.
Decreased plasma ghrelin levels in patients with advanced cancer
and weight loss in comparison to healthy individuals. Anticancer
Res. 2009;29:3949–52.
131. Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada
T, Hayashi Y, et al. Anti-cachectic effect of ghrelin in nude mice
bearing human melanoma cells. Biochem Biophys Res Commun.
2003;301:275–9.
132. Perboni S, Bowers C, Kojima S, Asakawa A, Inui A. Growth
hormone releasing peptide 2 reverses anorexia associated with
chemotherapy with 5-fluoruracil in colon cancer cell-bearing
mice. World J Gastroenterol. 2008;14:6303–5.
133. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, et al.
Ghrelin treatment of chronic kidney disease: improvements in
lean body mass and cytokine profile. Endocrinology.
2008;149:827–35.
134. Barazzoni R, Zhu X, Deboer M, Datta R, Culler MD, Zanetti M,
et al. Combined effects of ghrelin and higher food intake
enhance skeletal muscle mitochondrial oxidative capacity and
AKT phosphorylation in rats with chronic kidney disease.
Kidney Int. 2010;77:23–8.
135. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F,
Shimizu W, et al. Chronic administration of ghrelin improves left
ventricular dysfunction and attenuates development of cardiac
cachexia in rats with heart failure. Circulation. 2001;104:1430–5.
136. Akashi YJ, Palus S, Datta R, Halem H, Taylor JE, Thoene-Reineke
C, et al. No effects of human ghrelin on cardiac function despite
profoundeffectsonbodycompositioninaratmodelofheartfailure.
Int J Cardiol. 2009;137:267–75.
137. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten
Velde GP, Wouters EF. Effects of medroxyprogesterone acetate
on food intake, body composition, and resting energy expen-
diture in patients with advanced, nonhormone-sensitive cancer:
a randomized, placebo-controlled trial. Cancer. 1998;82:553–
60.
138. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR,
MacDonald N, et al. An eicosapentaenoic acid supplement
versus megestrol acetate versus both for patients with cancer-
associated wasting: a North Central Cancer Treatment Group and
National Cancer Institute of Canada collaborative effort. J Clin
Oncol. 2004;22:2469–76.
139. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu
W, et al. Effects of ghrelin administration on left ventricular
function, exercise capacity, and muscle wasting in patients with
chronic heart failure. Circulation. 2004;110:3674–9.
140. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake
K, et al. Treatment of cachexia with ghrelin in patients with
COPD. Chest. 2005;128:1187–93.
141. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D,
Tschöp M, et al. Safety, tolerability and pharmacokinetics of
intravenous ghrelin for cancer-related anorexia/cachexia: a
randomised, placebo-controlled, double-blind, double-crossover
study. Br J Cancer. 2008;98:300–8.
142. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C,
et al. Ghrelin increases energy intake in cancer patients with
impaired appetite: acute, randomized, placebo-controlled trial. J
Clin Endocrinol Metab. 2004;89:2832–6.
143. Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G,
Ghatei MA, et al. Subcutaneous ghrelin enhances acute food
intake in malnourished patients who receive maintenance
peritoneal dialysis: a randomized, placebo-controlled trial. J
Am Soc Nephrol. 2005;16:2111–8.
144. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical
guidelines for authorship and publishing in the Journal of
Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia
Muscle 2010;1:7–8.
J Cachexia Sarcopenia Muscle (2010) 1:135–145 145